BC Week In Review | Sep 29, 2017
Company News

Basilea grants China Resources Holdings rights to Zevtera in China

Basilea Pharmaceutica Ltd. (SIX:BSLN) granted the Shenzhen China Resources Gosun Pharmaceutical Co. Ltd. unit of China Resources Holding Co. Ltd. (Wanchai, China) exclusive rights to develop and commercialize antibiotic Zevtera ceftobiprole in China, including Hong...
BC Week In Review | Sep 19, 2016
Company News

Basilea, Grupo Biotoscana deal

Basilea granted Grupo Biotoscana exclusive rights to commercialize Cresemba isavuconazole and Zevtera ceftobiprole in 19 Latin American countries, including Argentina, Brazil, Columbia and Mexico. Basilea will receive CHF11 million ($11.3 million) up front and is...
BC Week In Review | Apr 25, 2016
Company News

Basilea, Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority awarded Basilea a four-and-a-half-year contract worth up to $100 million to support Phase III trials of the company’s ceftobiprole medocaril. Basilea markets the broad-spectrum cephalosporin antibiotic in Europe...
BC Extra | Apr 21, 2016
Company News

Basilea lands BARDA contract for ceftobiprole

Basilea Pharmaceutica AG (SIX:BSLN) said HHS's Biomedical Advanced Research and Development Authority awarded it a 4.5-year contract potentially worth $100 million to support Phase III trials of the company's ceftobiprole medocaril . Basilea markets the broad-spectrum...
BC Week In Review | Nov 16, 2015
Company News

Basilea, Hikma Pharmaceuticals deal

Basilea granted Hikma exclusive rights to commercialize Zevtera ceftobiprole in the Middle East and North Africa. The antibiotic is approved in Europe to treat adults with community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP), excluding ventilator-associated...
BC Week In Review | Sep 7, 2015
Clinical News

Zevtera ceftobiprole medocaril regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to Zevtera ceftobiprole medocaril from Basilea to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The antibiotic is approved in Europe...
BioCentury | Aug 3, 2015
Finance

Taiwan's post-bubble prognosis

More than a year after BioCentury chronicled investor enthusiasm for biotechs in Taiwan, the bubble has deflated. It's tempting to blame the downturn simply on retail investors who didn't get up to speed as quickly...
BC Week In Review | Feb 2, 2015
Clinical News

Zevtera ceftobiprole medocaril regulatory update

Basilea said Switzerland approved Zevtera ceftobiprole medocaril to treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), in adults. Zevtera was approved under the EU’s decentralized procedure and has received national approvals...
BC Week In Review | Dec 15, 2014
Company News

Basilea sales and marketing update

Basilea launched Zevtera ceftobiprole in Germany to treat bacterial lung infections. The product is a broad-spectrum cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA). Basilea could not be reached for details. Basilea Pharmaceutica AG...
BC Week In Review | Aug 18, 2014
Company News

Basilea, Quintiles deal

Quintiles will provide Basilea commercial services for the European launch of Basilea’s Zevtera ceftobiprole. The broad-spectrum cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) is approved in Europe to treat community- and hospital-acquired pneumonia...
Items per page:
1 - 10 of 205